Algert Global LLC Sells 20,631 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Algert Global LLC decreased its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 27.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 54,983 shares of the biopharmaceutical company's stock after selling 20,631 shares during the quarter. Algert Global LLC owned 0.08% of Celldex Therapeutics worth $1,869,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in CLDX. Charles Schwab Investment Management Inc. lifted its stake in shares of Celldex Therapeutics by 1.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 538,856 shares of the biopharmaceutical company's stock valued at $18,316,000 after purchasing an additional 8,413 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Celldex Therapeutics during the 3rd quarter worth about $871,000. Jennison Associates LLC increased its holdings in shares of Celldex Therapeutics by 32.0% during the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company's stock valued at $45,017,000 after acquiring an additional 321,325 shares during the last quarter. KBC Group NV lifted its holdings in Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 495 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its position in Celldex Therapeutics by 191.2% during the third quarter. GSA Capital Partners LLP now owns 16,114 shares of the biopharmaceutical company's stock worth $548,000 after purchasing an additional 10,581 shares during the period.

Analysts Set New Price Targets

Several research firms recently issued reports on CLDX. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Monday, September 16th. Citigroup initiated coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They set a "buy" rating and a $70.00 price objective on the stock. Wolfe Research cut Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday, September 27th. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Wednesday, November 20th. Finally, The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They set a "neutral" rating and a $45.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $62.25.

Insiders Place Their Bets

In other news, CEO Anthony S. Marucci acquired 11,500 shares of Celldex Therapeutics stock in a transaction dated Monday, November 11th. The shares were bought at an average cost of $26.82 per share, with a total value of $308,430.00. Following the purchase, the chief executive officer now owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 3.80% of the company's stock.

Celldex Therapeutics Trading Up 4.2 %

Shares of NASDAQ:CLDX traded up $1.13 on Thursday, hitting $27.89. The company had a trading volume of 766,814 shares, compared to its average volume of 886,809. The stock has a 50 day moving average price of $29.35 and a 200 day moving average price of $34.60. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -10.85 and a beta of 1.60. Celldex Therapeutics, Inc. has a 1-year low of $22.93 and a 1-year high of $53.18.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.